CKD-512 with or without pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, CKD-512, alone or combined with pembrolizumab, in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if this therapy can help when other options are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumor confirmed by biopsy
- Your tumor has gotten worse during or after standard treatment, and no other effective treatments are available
- Your tumors can be measured on scans (RECIST criteria)
- You are able to do your daily activities without much help (ECOG score of 0 or 1)
- You have adequate blood counts and organ function
- You have not had brain metastases that are active or untreated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests two experimental drugs, PE0116 and PE0105, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the combination is safe and effective for cancers like kidney, head and neck, cervical, or ovarian cancer.
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.